Insulin is often required in many patients with type 2 diabetes mellitus because of disease progression and the loss of pancreatic β-cell insulin secretion. Ideally, exogenously administered insulin mimics the physiologic profile of endogenous insulin secretion in healthy persons. New insulin formulations have been developed to improve the physiologic profile in patients with diabetes, which may decrease the risk of hypoglycemia and weight gain. In this online educational activity, the faculty sets the stage for the second module in the series by reviewing the efficacy and safety of basal insulin in managing type 2 diabetes, focusing on newer insulin therapies. Evidence from clinical trials supporting glycemic and cardiovascular benefits of diabetes therapies is reviewed, and the clinical profiles of different insulin products are compared with respect to dosing, variability, volume, and safety.